 |
|
|
| |
Coadministration of Ritonavir with the HCV Protease Inhibitor Danoprevir Substantially Reduces
Reactive Metabolite Formation Both In Vitro and In Vivo
|
| |
| |
Reported by Jules Levin
AASLD Nov 9-13 2012 Boston
P. Goelzer,1 P.N. Morcos,1 J.Q. Tran,2 B. Wen,1 N.S. Shulman,3 B.J. Brennan,1 J. Hammond,1 T. Singer,4 P. Smith1
1Hoffmann-La Roche Inc, Nutley, NJ, USA; 2Hoffmann-La Roche Inc. Palo Alto, CA, USA; 3Genentech, South San Francisco, CA, USA; 4F. Hoffmann-La Roche Ltd, Basel, Switzerland
|
| |
|
|
|
|
|
